HCM
TEVA icon

Highfields Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Highfields Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-5,295,102
Closed -$83M – 11
2019
Q1 		$83M Sell
5,295,102
-6,500,000
-55% -$115M 11.41% 4
2018
Q4 		$182M Sell
11,795,102
-2,266,054
-16% -$46.5M 8.57% 3
2018
Q3 		$303M Sell
14,061,156
-13,038,477
-48% -$303M 5.66% 3
2018
Q2 		$659M Sell
27,099,633
-10,117,250
-27% -$206M 7.25% 3
2018
Q1 		$636M Buy
37,216,883
+2,464,556
+7% +$48.1M 5.76% 4
2017
Q4 		$659M Buy
34,752,327
+9,171,368
+36% +$138M 5.47% 4
2017
Q3 		$450M Buy
25,580,959
+4,205,045
+20% +$94.6M 3.88% 8
2017
Q2 		$710M Buy
21,375,914
+3,657,564
+21% +$113M 5.26% 4
2017
Q1 		$569M Buy
17,718,350
+850,903
+5% +$29M 5.27% 4
2016
Q4 		$611M Buy
16,867,447
+8,686,905
+106% +$347M 5.07% 5
2016
Q3 		$376M Sell
8,180,542
-5,368,983
-40% -$280M 3.53% 9
2016
Q2 		$681M Buy
13,549,525
+3,958,375
+41% +$211M 5.93% 1
2016
Q1 		$513M Buy
9,591,150
+1,098,246
+13% +$64.4M 4.79% 4
2015
Q4 		$557M Buy
8,492,904
+200,000
+2% +$12.4M 4.8% 4
2015
Q3 		$468M Buy
8,292,904
+3,824,550
+86% +$248M 4.13% 7
2015
Q2 		$264M Sell
4,468,354
-617,551
-12% -$38.1M 2.37% 13
2015
Q1 		$317M Hold
5,085,905
– – 2.83% 12
2014
Q4 		$292M Sell
5,085,905
-1,287,095
-20% -$71.7M 2.49% 14
2014
Q3 		$343M Buy
6,373,000
+186,000
+3% +$9.85M 2.67% 13
2014
Q2 		$324M Buy
6,187,000
+187,000
+3% +$9.56M 2.38% 11
2014
Q1 		$317M Buy
+6,000,000
New +$277M 2.66% 12
2013
Q3 		– Sell
-1,539,728
Closed -$60.4M – 101
2013
Q2 		$60.4M Buy
+1,539,728
New +$60M 0.5% 55

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Highfields Capital Management's TEVA Position: Q2 2019 in Review

Highfields Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2019, closing a stake of 5,295,102 shares — an estimated $83M sold.

Highfields Capital Management first reported a position in TEVA in Q2 2013 and held it in 22 quarters. The position peaked at $710M in Q2 2017. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

  • Highfields Capital Management reported no remaining Teva Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Highfields Capital Management sold 5,295,102 Teva Pharmaceuticals shares in Q2 2019, an estimated $83M.
  • Highfields Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Highfields Capital Management's Teva Pharmaceuticals position peaked at $710M in Q2 2017.
  • 452 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2019.

Based on Highfields Capital Management's 13F filing for Q2 2019, filed 12 Aug 2019.